Selectively targeting mutant BRAF in thyroid cancer (Q42938752)

11 November 2017

0 references

Selectively targeting mutant BRAF in thyroid cancer (English)

1 reference

11 November 2017

Douglas W Ball

1

1 reference

PMC publication ID

2805482

11 November 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

The Journal of Clinical Endocrinology and Metabolism

11 November 2017

1 reference

11 November 2017

95

1 reference

11 November 2017

1

1 reference

11 November 2017

60-61

1 reference

Targeting the RAF-MEK-ERK pathway in cancer therapy

11 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805482

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805482

Phase II trial of sorafenib in advanced thyroid cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805482

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805482

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805482

BRAF mutation predicts sensitivity to MEK inhibition

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805482

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805482

Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805482

Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805482

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805482

BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20056810

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

BRAF Mutation in Papillary Thyroid Carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20056810

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1210/JC.2009-2332

1 reference

11 November 2017

1 reference

PMC publication ID

2805482

11 November 2017

PubMed publication ID

20056810

1 reference

PMC publication ID

2805482